CPC-111 metabolic energy intermediate data

CYPR presented results from an ongoing double-blind, placebo-controlled Phase II trial in the U.K. in CABG patients, showing statistically significant reductions in heart injury

Read the full 248 word article

How to gain access

Continue reading with a
two-week free trial.